Peptidomimetic macrocycles and formulations thereof
Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
1. An aqueous pharmaceutical formulation in a unit dosage form comprising:
a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof, wherein the peptidomimetic macrocycle has an amino acid sequence identical to a sequence of any one of SEQ ID NOs: 339, 350, 351, 446, 447, 453, 457-459, 472-475, 478-481, 484, 485, 486, 492, 493, and 499, and wherein the peptidomimetic macrocycle is present in the aqueous pharmaceutical formulation in an amount of about 15-20 mg/mL;
(ii) a buffering agent at a concentration of 20 mM, wherein the buffering agent is a sodium phosphate;
(iii) a stabilizing agent in an amount of 300 ppm in the aqueous pharmaceutical formulation, wherein the stabilizing agent is polysorbate 20;
(iv) a tonicity agent in a concentration of about 240 mM in the aqueous pharmaceutical formulation, wherein the tonicity agent is trehalose;
wherein the peptidomimetic macrocycle has a Formula I:
wherein
each D, Xaa 5 , Xaa 6 , Xaa 8 , Xaa 9 , and E is independently an amino acid;
each E is independently selected from Ala, D-Ala, Aib, Sar, and Ser;
[D] v is Leu 1 -Thr 2 ;
Xaa 3 is Phe;
Xaa 7 is Trp;
Xaa 10 is Leu;
each R 1 and R 2 is independently alkyl;
L is a macrocycle-forming linker;
R 7 is —H;
R 8 is —H; and
w is an integer from 1-10.
2. The aqueous pharmaceutical formulation of claim 1 , wherein the peptidomimetic macrocycle has a length value of from 14 to 20 amino acids.
3. The aqueous pharmaceutical formulation of claim 1 , wherein the peptidomimetic macrocycle has a von Heijne value of from 2 to 9.
4. The aqueous pharmaceutical formulation of claim 1 , wherein the peptidomimetic macrocycle has a percent alanine content of from 15% to 40%.
5. The aqueous pharmaceutical formulation of claim 1 , wherein a first, second, third, fourth, fifth, or sixth C-terminal amino acid of the peptidomimetic macrocycle is hydrophobic.
6. The aqueous pharmaceutical formulation of claim 1 , wherein the peptidomimetic macrocycle comprises an α-helix.
7. The aqueous pharmaceutical formulation of claim 1 , wherein the pharmaceutically acceptable salt of the peptidomimetic macrocycle is a sodium, potassium, lithium, calcium, zinc, or magnesium salt.
8. The aqueous pharmaceutical formulation of claim 1 , wherein total peptidomimetic degradation products formed in the aqueous pharmaceutical formulation is less than 1.0% when stored at a temperature of 40° C. for a period of one month.
9. The aqueous pharmaceutical formulation of claim 1 , wherein the aqueous pharmaceutical formulation upon storage for 24 months at from about 2° C. to about 8° C. comprises at least 95% of an amount of the peptidomimetic macrocycle present prior to the storage for 24 months.
10. The aqueous pharmaceutical formulation of claim 1 , wherein an osmolarity of the aqueous pharmaceutical formulation is from about 250 to about 1000 milliosmoles per kilogram.
11. The aqueous pharmaceutical formulation of claim 1 further comprising glucose, fructose, galactose, sucrose, lactose, maltose, or a mixture thereof.
12. The aqueous pharmaceutical formulation of claim 1 , wherein the tonicity agent is D-trehalose.
13. The aqueous pharmaceutical formulation of claim 1 , wherein the aqueous pharmaceutical formulation has a pH from about 6.0 to about 8.0.
14. The aqueous pharmaceutical formulation of claim 1 , wherein the aqueous pharmaceutical formulation has a pH from about 4.0 to about 9.0.
15. The aqueous pharmaceutical formulation of claim 1 , wherein the peptidomimetic macrocycle has a molecular weight in the range of 1800-2000 D.
16. A method of making an aqueous pharmaceutical formulation comprising adding greater than 15 mg/mL of a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof to water or an aqueous solution, wherein the aqueous pharmaceutical formulation comprises less than 2% w/v of any micelle forming agent.
17. The method of claim 16 , wherein the peptidomimetic macrocycle is capable of binding to the MDM2 and/or MDMX proteins.
18. The method of claim 16 , comprising adding a sodium salt of the peptidomimetic macrocycle to water or an aqueous solution.
19. The method of claim 16 , further comprising adjusting the pH of the solution comprising the buffering agent and the stabilizing agent during the addition of the peptidomimetic macrocycle.
20. The method of claim 16 , further comprising filtration of the aqueous pharmaceutical formulation obtained after the addition of the peptidomimetic macrocycle to the aqueous solution.
21. The method of claim 16 , wherein the method is used for commercial manufacturing of the aqueous pharmaceutical formulation.
22. The aqueous pharmaceutical formulation of claim 1 , wherein the amino acid sequence is SEQ ID NO. 339.
23. The aqueous pharmaceutical formulation of claim 1 , wherein the amino acid sequence is SEQ ID NO. 499.
24. The aqueous pharmaceutical formulation of claim 1 , wherein the aqueous pharmaceutical formulation is suitable for administration to a subject without dilution.